Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Information source: The Cleveland Clinic
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Workplace Migraine Treatment
Intervention: Usual prescribed triptan (Drug); Treximet for migraine treatment (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: The Cleveland Clinic Overall contact:
Stewart J Tepper, MD, Phone: 216/636-5549, Email: teppers@ccf.org
Summary
Researchers want to learn about work productivity after treatment of a migraine headache
with your usual migraine medication as compared to your work productivity after treatment
with Treximet.
During this research subjects will take Treximet to treat 3 workday migraine attacks. For a
second part of the research subjects will take their usual prescribed medication for 3
workday migraine attacks. The subjects will complete questionnaires after treating each
migraine.
Clinical Details
Official title: A Single Center, Randomized, Open-Label, Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan. Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Primary outcome: workplace productivity compared between migraines treated with usual triptan versus migraines treated with Treximet
Secondary outcome: comparison of patient completeness of response to migraine treatments across 6 treated workplace migraines
Detailed description:
A subject who is identified for study participation will participate in the screening and
enrollment visit which determines the migraine treatment arm to which the subject will be
randomized first. The subject will have a physical exam, vital signs recorded, health and
medication questions asked, questionnaires completed and a headache diary explained and
dispensed to the subject. If the subject is randomized to the Treximet treatment arm during
the first part of the study, Treximet will be dispensed for use in treating workday
migraines.
The subject will call the study coordinator after treating a workday migraine and will
report information about the migraine to the coordinator. When the subject has treated and
reported on 3 migraines, the interim visit will be scheduled. The subject will bring the
study diary and Treximet containers (if this was the arm the subject completed)to this
visit. The subject will be asked about adverse events and medication changes as well as
confirmation and review of the completed questionnaires and diaries from the prior weeks of
study participation. The subject will be given new diaries and questionnaires (and Treximet
to use if usual prescribed triptan was the treatment in the first arm) and repeat the
activities to treat 3 more workday migraines.
When the subject has notified the study coordinator about treating the 3rd workday migraine
in this part of the study, the subject will be scheduled for the final study visit. The
subject will bring the completed migraine diaries, completed questionnaires (and Treximet
bottles if used during this arm) to the study visit. The subject will have the diaries and
questionnaires reviewed, be asked about adverse events and medication changes and complete
the final study questionnaires at this visit.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- episodic migraine diagnosis
- age 18 or older
- currently using a triptan as primary migraine monotherapy
- currently employed
- if of childbearing potential, willing to prevent pregnancy during study participation
- able to understand and consent to study participation
Exclusion Criteria:
- younger than age 18
- not having episodic migraine diagnosis
- not using a triptan as primary migraine monotherapy
- not currently employed
- pregnant or nursing or unwilling to prevent pregnancy during study participation
- unable to understand and consent to study participation
Locations and Contacts
Stewart J Tepper, MD, Phone: 216/636-5549, Email: teppers@ccf.org
Cleveland Clinic, 9500 Euclid Avenue, T-33, Cleveland, Ohio 44195, United States; Recruiting
Stewart J Tepper, MD, Phone: 216-636-5549, Email: teppers@ccf.org
Mary R Horvat, BA, Phone: 216/445-1947, Email: horvatm@ccf.org
Additional Information
Related publications: Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009 Jul;49(7):971-82. Epub 2009 May 27. Dowson AJ, Tepper SJ, Baos V, Baudet F, D'Amico D, Kilminster S. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin. 2004 Jul;20(7):1125-35. Cleves C, Tepper SJ. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother. 2008 Sep;8(9):1289-97. Review. Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4;297(13):1443-54.
Starting date: September 2009
Last updated: December 11, 2012
|
